Japanese Bio StartUp CLOVERNA announces a pre-seed round by VC in Tokyo
The pre-seed round was funded by Keio Innovation Initiative, Inc. and backed CLOVERNA's first raise.
By: CLOVERNA, Inc.
The funds will be used to move their collaborative research and development projects for RNA therapeutics forward.
CLOVERNA, the Okayama, Japan-based, first Kawasaki Medical School-led startup company working with biotechnology to develop RNA therapeutic drugs, announced on June 30, 2022, that it has completed its pre-seed funding round by Keio Innovation Initiative VC in Tokyo. Founder Dr. Tatsuo Ito and Co-founder Dr. Yurika Shimizu together invented their innovative biotechnology to change the world of RNA drug discovery technology.
CLOVERNA's mission is:
" Exploring unknown RNA drug targets and bringing new hope to all patients."
With the next funding, they are aiming to expand their labs to the United States.
Dr. Tasuo Ito, a professor at Kawasaki Medical School's Hygiene Department, launched CLOVERNA in 2020. Dr. Ito and co-founder Dr. Yurika Shimizu developed a unique RNA drug discovery technology.
They aim to break into a dark matter RNA, that is 40 times more plentiful than proteins, using their RNA drug treatment discovery system.
CLOVERNA's approach represents a paradigm shift in drug discovery, promising two major aspects: (1) discovering new RNA molecules in cell types (2) targeting previously undruggable pathways with a more personalized strategy that can target and combat difficult-to-
To learn more, visit https://www.CLOVERNA.com
Page Updated Last on: Aug 30, 2022